September D-Day for 3rd-gen contraceptives
This article was originally published in Scrip
Executive Summary
The European Medicines Agency says it has widened the scope of its safety review of third-generation contraceptives and is gathering information from a range of sources including new EU drug utilisation studies. A conclusion on the products' benefit-risk profile is expected by September, Noël Wathion, the agency's head of patient health protection, told a meeting of the European Parliament's environment and public health committee (ENVI) on 26 March.